Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 7/20 | 0.57 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.57 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.57 |
| ▸ | F10 | P00742 | 2/20 | 0.57 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.57 |
| ▸ | F2 | P00734 | 6/20 | 0.48 |
| ▸ | ST14 | Q9Y5Y6 | 3/20 | 0.48 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | PLG | P00747 | 1/20 | 0.47 |
| ▸ | C1S | P09871 | 1/20 | 0.47 |
| ▸ | MASP2 | O00187 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL48986 | 0.79 | PRSS1 (0.57) | PRSS1PRSS3PRSS2F10LOXL2 | |
| SCHEMBL8178806 | 0.79 | CYP2C9 (0.37) | PRSS1PRSS3PRSS2F10LOXL2 | |
| SCHEMBL10209044 | 0.79 | PLA2G10 (0.52) | — | |
| SCHEMBL20880153 | 0.76 | PRSS1 (0.53) | PRSS1PRSS3PRSS2F10LOXL2 | |
| SCHEMBL12085592 | 0.76 | PRSS1 (0.56) | PRSS1PRSS3PRSS2F10LOXL2 | |
| SCHEMBL13714812 | 0.76 | PRSS1 (0.53) | PRSS1PRSS3PRSS2F10LOXL2 | |
| SCHEMBL2717268 | 0.75 | PRSS1 (0.70) | PRSS1PRSS3PRSS2F10LOXL2 | |
| SCHEMBL19080482 | 0.75 | PRSS1 (0.52) | PRSS1PRSS3PRSS2F10LOXL2 | |
| SCHEMBL12085588 | 0.75 | PRSS1 (0.58) | PRSS1PRSS3PRSS2F10LOXL2 | |
| SCHEMBL12083000 | 0.75 | PRSS1 (0.58) | PRSS1PRSS3PRSS2F10LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | PRSS1 62/4885PRSS3 59/4885PRSS2 148/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | PRSS1 62/4885PRSS3 59/4885PRSS2 148/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | PRSS1 62/4885PRSS3 59/4885PRSS2 148/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | PRSS1 62/4885PRSS3 59/4885PRSS2 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.